Korean Pharma Develops New Oral Disintegrating Tablet Formulation of Rosuzet with Rexfarmtech
Korea Pharma is set to develop an orally disintegrating tablet of ‘Rosujet,’ the top outpatient prescription item for hyperlipidemia treatment.
On the 7th, Korea Pharma announced that it has signed a joint development agreement with pharmaceutical development specialist Rex Pharm Tech for an orally disintegrating tablet of the rosuvastatin and ezetimibe combination drug. It also plans to sign a clinical trial contract with the Korea Medical Research Institute (KMRI) for product approval.
Under the agreement, Korea Pharma will be responsible for the approval, production, and sales of the orally disintegrating tablet containing the same active ingredients as Rosujet. After product approval, it plans to offer contract manufacturing (CMO) services to pharmaceutical companies wishing to sell the product.
The rosuvastatin and ezetimibe combination drug, well known as a hyperlipidemia treatment, has a domestic prescription sales volume exceeding 600 billion KRW. One of the representative combination drugs, Hanmi Pharmaceutical’s Rosujet, is the number one outpatient prescription item in Korea, surpassing 100 billion KRW in prescription sales in the first half of this year alone.
In particular, Korea Pharma and Rex Pharm Tech will develop the drug as an orally disintegrating tablet, differing from the existing combination drug formulations. Considering the characteristics of hyperlipidemia patients, who are predominantly elderly, they aim to significantly improve medication convenience and aggressively target the market.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
A company official stated, "Like hypertension and diabetes treatments, the domestic hyperlipidemia treatment market is continuously growing annually due to population aging and changes in dietary habits. We will actively target the domestic hyperlipidemia treatment market with a new orally disintegrating tablet formulation in partnership with Rex Pharm Tech.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
